Avenge Bio, Inc
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary (NCT05538624) | Avenge Bio, Inc | 2022-12-09 |
Track Avenge Bio, Inc automatically
Every clearance here is in the API, with alerts when new ones post.